STOCK TITAN

Takeda (NYSE: TAK) director details RSU, tax awards and share holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Takeda Pharmaceutical director John Maraganore reports his equity interests in the company. He shows direct holdings of 7,600 American Depositary Shares and 9,700 Ordinary Shares, along with Tax Obligation Awards that are economically equivalent to 1,152, 1,192 and 1,180 Ordinary Shares.

The filing also describes restricted stock unit awards that each convert into one Ordinary Share and then into an equivalent number of American Depositary Shares. These RSUs vest in tranches of 3,100, 3,400 and 3,200 shares on June 1, 2026, June 1, 2027 and June 1, 2028, respectively.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
MARAGANORE JOHN

(Last)(First)(Middle)
75 SIDNEY STREET

(Street)
CAMBRIDGE MASSACHUSETTS 02139

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares7,600D
Ordinary Shares9,700(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Tax Obligation Award06/01/202606/01/2026Ordinary Shares1,152(2)D
Tax Obligation Award06/01/202706/01/2027Ordinary Shares1,192(2)D
Tax Obligation Award06/01/202806/01/2028Ordinary Shares1,180(2)D
Explanation of Responses:
1. Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on the following schedule: June 1, 2026 (3,100 shares), June 1, 2027 (3,400 shares) and June 1, 2028 (3,200 shares).
2. Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Remarks:
Exhibit 24 Power of Attorney
/s/ Max Heuer, by power of attorney, for John Maraganore03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Takeda (TAK) director John Maraganore report owning in this Form 3?

He reports direct holdings of 7,600 American Depositary Shares and 9,700 Ordinary Shares. He also lists Tax Obligation Awards tied to Ordinary Shares and separate restricted stock unit awards that vest over time into additional equity-linked value.

What are the Tax Obligation Awards reported by Takeda (TAK) director John Maraganore?

The Tax Obligation Awards are noted as the economic equivalent of Ordinary Shares that, upon vesting, convert into cash payments. These payments primarily cover tax obligations at the then-current market price of Takeda’s Ordinary Shares, rather than delivering additional stock.

What restricted stock units (RSUs) does John Maraganore report for Takeda (TAK)?

He reports RSU awards where each unit represents a contingent right to receive one Ordinary Share. After vesting, these Ordinary Shares are converted into an equivalent number of American Depositary Shares, giving him future share-based compensation if vesting conditions are met.

What is the vesting schedule for John Maraganore’s Takeda (TAK) RSUs?

The RSUs vest in three tranches: 3,100 shares on June 1, 2026, 3,400 shares on June 1, 2027, and 3,200 shares on June 1, 2028. Each vested RSU converts into one Ordinary Share, then into equivalent American Depositary Shares.

Does this Takeda (TAK) Form 3 show insider buying or selling by John Maraganore?

The data presented reflects holdings and equity-based awards rather than explicit open-market purchases or sales. It outlines his existing share interests, RSU grants, and Tax Obligation Awards, providing a snapshot of his compensation-related exposure to Takeda stock.
Takeda Pharm

NYSE:TAK

View TAK Stock Overview

TAK Rankings

TAK Latest News

TAK Latest SEC Filings

TAK Stock Data

57.06B
3.16B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Japan
Tokyo